Steven George Hughes sold $3.5M of RNA
Chief Medical Officer at Avidity Biosciences, Inc.. 81,434 shares at an average of $42.74, traded Aug 6, 2025, filed Aug 8, 2025.
Score components
- +15RoleOfficer
- +25Trade size$3.5M at market
- +20Share of holdings soldSold 97% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001599901-25-000150, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 6, 2025 | MOption exercise Common Stock10b5-1 | +11,283 | $15.96 | $180k | 84,133 | Aug 8, 2025 |
| Aug 6, 2025 | SOpen-market sale Common Stock10b5-1 | -11,283 | $42.74 | $482k | 72,850 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Common Stock10b5-1 | +12,334 | $6.57 | $81k | 85,184 | Aug 8, 2025 |
| Aug 6, 2025 | SOpen-market sale Common Stock10b5-1 | -12,334 | $42.74 | $527k | 72,850 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Common Stock10b5-1 | +6,167 | $22.47 | $139k | 79,017 | Aug 8, 2025 |
| Aug 6, 2025 | SOpen-market sale Common Stock10b5-1 | -6,167 | $42.74 | $264k | 72,850 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Common Stock10b5-1 | +17,667 | $10.16 | $179k | 90,517 | Aug 8, 2025 |
| Aug 6, 2025 | SOpen-market sale Common Stock10b5-1 | -17,667 | $42.74 | $755k | 72,850 | Aug 8, 2025 |
| Aug 6, 2025 | SOpen-market sale Common Stock10b5-1 | -33,983 | $42.74 | $1.5M | 38,867 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,283 | $0.00 | $0 | 73,342 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,334 | $0.00 | $0 | 52,417 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,167 | $0.00 | $0 | 74,000 | Aug 8, 2025 |
| Aug 6, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,667 | $0.00 | $0 | 75,083 | Aug 8, 2025 |
Related signals
Other insiders at Avidity Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | Avidity Biosciences, Inc. | Teresa McCarthy Chief Human Resources Officer | $212k 2,929 shares | -3% | |
| 21Weak | Avidity Biosciences, Inc. | Arthur A Levin director | $127k 1,758 shares | -10% | |
| 32Weak | Avidity Biosciences, Inc. | Michael F MacLean Chief Financial Officer | $329k 4,542 shares | -7% | |
| 27Weak | Avidity Biosciences, Inc. | W. Michael Flanagan Chief Scientific Officer | $473k 6,534 shares | -7% | |
| 45Moderate | Avidity Biosciences, Inc. | Sarah Boyce President and CEO | $1.0M 14,387 shares | -5% | |
| 30Weak | Avidity Biosciences, Inc. | Steven George Hughes Chief Medical Officer | $355k 4,895 shares | -13% | |
| 21Weak | Avidity Biosciences, Inc. | W. Michael Flanagan Chief Scientific Officer | $171k 2,373 shares | -3% | |
| 21Weak | Avidity Biosciences, Inc. | Steven George Hughes Chief Medical Officer | $171k 2,373 shares | -6% | |
| 28Weak | Avidity Biosciences, Inc. | Michael F MacLean Chief Financial Officer | $143k 1,974 shares | -3% | |
| 21Weak | Avidity Biosciences, Inc. | John B Moriarty Chief Legal Officer | $171k 2,374 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.